Cooperation on the Development of a Malaria Vaccine
The malaria vaccine GMZ2 to be tested in a Phase I clinical trial in Tübingen
Vakzine Projekt Management GmbH (VPM) and the European malaria Vaccine Initiative (EMVI) are cooperating in compiling and submitting the Phase I clinical trial application of malaria vaccine GMZ2 to the Paul-Ehrlich-Institute and to the Ethics Committee Tübingen, Germany. In addition, VPM shall provide regulatory support during the evaluation phase, and will be the liaison partner with the authorities during this period.
GMZ2 (GLURP-MSP3 bivalent vaccine) is a recombinant hybrid protein of GLURP and MSP3 expressed in the L. lactis expression system. GMZ2 is derived from Plasmodium falciparum Glutamate-Rich Protein (GLURP), genetically coupled to P. falciparum Merozoite Surface Protein 3 (MSP3). The aim of the Phase I trial is to evaluate the safety of 3 dosages of GMZ2 (10 µg, 30 µg or 100 µg) adjuvanted with aluminium hydroxide (alum) and given three times over a two month period to healthy adults not previously exposed to the malaria parasite Plasmodium falciparum. The study will take place at the University of Tübingen.
Other news from the department science
